Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immunome, Inc. - Common Stock
(NQ:
IMNM
)
20.11
+0.13 (+0.65%)
Streaming Delayed Price
Updated: 2:04 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunome, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
October 18, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 11, 2024
Via
Benzinga
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
Evaluating Immunome: Insights From 4 Financial Analysts
↗
May 31, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 01, 2024
Via
Benzinga
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Stock Sees RS Rating Jump To 91
↗
August 20, 2024
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
Via
Investor's Business Daily
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
↗
August 12, 2024
IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
July 25, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Phil Tsai as Chief Technical Officer
June 27, 2024
From
Immunome, Inc.
Via
Business Wire
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
↗
May 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 21, 2024
Via
Benzinga
Immunome Announces Completion of Purchase of Assets from Atreca
May 20, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
May 17, 2024
From
Immunome, Inc.
Via
Business Wire
IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024
↗
May 14, 2024
IMNM stock results show that Immunome beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 2024 Bank of America Healthcare Conference
May 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Kinney Horn as Chief Business Officer
May 02, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Sandra M. Swain to Board of Directors
April 25, 2024
From
Immunome
Via
Business Wire
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
April 05, 2024
From
Immunome, Inc.
Via
Business Wire
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
↗
March 28, 2024
IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
March 28, 2024
From
Immunome, Inc.
Via
Business Wire
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
↗
March 28, 2024
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.
Via
Benzinga
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 26, 2024
From
Immunome, Inc.
Via
Business Wire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
↗
March 22, 2024
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
Via
Benzinga
Topics
Stocks
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
